Title |
The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
|
---|---|
Published in |
Retrovirology, January 2014
|
DOI | 10.1186/1742-4690-11-7 |
Pubmed ID | |
Authors |
Melissa Wares, Thibault Mesplède, Peter K Quashie, Nathan Osman, Yingshan Han, Mark A Wainberg |
Abstract |
First-generation integrase strand-transfer inhibitors (INSTIs), such as raltegravir (RAL) and elvitegravir (EVG), have been clinically proven to be effective antiretrovirals for the treatment of HIV-positive patients. However, their relatively low genetic barrier for resistance makes them susceptible to the emergence of drug resistance mutations. In contrast, dolutegravir (DTG) is a newer INSTI that appears to have a high genetic barrier to resistance in vivo. However, the emergence of the resistance mutation R263K followed by the polymorphic substitution M50I has been observed in cell culture. The M50I polymorphism is also observed in 10-25% of INSTI-naïve patients and has been reported in combination with R263K in a patient failing treatment with RAL. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 33% |
Netherlands | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Scientists | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 48 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 9 | 19% |
Student > Master | 9 | 19% |
Researcher | 7 | 15% |
Other | 3 | 6% |
Student > Bachelor | 2 | 4% |
Other | 8 | 17% |
Unknown | 10 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 21% |
Biochemistry, Genetics and Molecular Biology | 9 | 19% |
Agricultural and Biological Sciences | 7 | 15% |
Immunology and Microbiology | 7 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
Other | 4 | 8% |
Unknown | 10 | 21% |